Since, in the human ureter, both beta(2)- and beta(3)-adrenoceptors mediate
adrenergic-stimulation-induced relaxation, selective beta(2)-/beta(3)-
adrenoceptor agonists might prove clinically useful for relieving
ureteral colic and promoting stone passage. We evaluated the beta-
adrenoceptor subtype selectivity and ureteral-relaxing efficacy of (-)-2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amin] ethyl)phenyloxy]
acetic acid (KUL-7211), a new beta-
adrenoceptor agonist, in vitro. In rat isolated organs, its selectivities, for inhibition of spontaneous uterine contraction (mediated via beta(2)-
adrenergic stimulation) and inhibition of colonic contraction (via beta(3)-
adrenergic stimulation) versus increase in atrial rate (via beta(1)-
adrenergic stimulation), were 56.3 and 242.2, respectively.
KUL-7211 relaxed 80-mM-KCl-induced tonic contractions in both rabbit (pD(2) value: 5.86 +/- 0.13, whose ureteral relaxation is mediated via beta(2)-
adrenergic stimulation) and canine (pD(2) value: 6.52 +/- 0.16, via beta(3)-
adrenergic stimulation) isolated ureters in a concentration-dependent manner. These KUL-7211-induced relaxing effects were antagonized by ICI-118,551 (selective beta(2)-
adrenoceptor antagonist, pK(B) value: 8.91 +/- 0.24) in the rabbit ureter and by
bupranolol (non-selective beta-adernoceptor antagonist, pK(B) value: 6.85 +/- 0.12) in the canine ureter.
KUL-7211 also reduced the spontaneous rhythmic contraction in a canine ureteral spiral preparation in a concentration-dependent manner, the pD(2) value being 6.83 +/- 0.20. These data clearly demonstrate that
KUL-7211 selectively stimulates both ureteral beta(2)- and beta(3)-adrenoceptors and potently relaxes ureteral smooth muscle.
KUL-7211 may be a novel and useful medication for relieving
ureteral colic and promoting stone passage in
urolithiasis patients.